Progress in medicine depends heavily on research, especially well-designed and executed clinical studies, as well as discoveries and innovations made by doctors using FDA-approved drugs and treatment methods (and in some cases supplements, for example, herbs, vitamins, amino acids, etc. .) on new methods and combinations in the treatment of patients (“messing around in the office” or experimenting, one might say). As long as the applied doctor does not establish a “new drug” according to FDA criteria and does not violate the agency rules governing new devices or what the doctor does, it is considered a medicine practice and is governed exclusively by him or Egypt by her state medical council.
If the physician was to treat ulcers using a combination of an approved drug, such as cimetidine (tagamet) and a herbal ulcer product, such a decyclized (DGL) licorice, this falls under the practice of medicine and is a form of low-risk medical experiments that most public medical advice admits to satisfied the requirements of informed consent, that is, the patient is told about known and perceived risks, side effects or complications (forms of more high-risk experiments may require that the treatment regimen or protocol be approved by the Board of Inquiry, as an ethics board). If this particular combination has occurred to heal ulcers better and more reliably than just one drug, this will be an innovation that moves the medicine forward. If the doctor on the other side wanted to try a cancer treatment drug that was approved in the EU, but not in the US, he would have to follow the rules and procedures of the FDA regarding new drugs. For example, he may receive permission to use the drug by submitting an application for an emergency medical examination (a new drug study), and this review will be reviewed by FDA officials. If they felt the benefits of risk v. The advantage of using in this case, they would give the doctor a new medicine permit (IND) for a single use of the anticancer drug in question.
But what if the doctor wanted to use stem cells from the patient’s own body to treat his arthritic knees and a bad back? Given the fact that there is no risk of rejection, will the FDA issue a question with a doctor taking their own stem cells or stem cells from the bone marrow and damaging their bad knees and back?
The answer depends on what is done with the stem cells and how they are controlled.
If the doctor wants to take the patient’s bone marrow stem cells, then cultivate them and increase their number or otherwise process them in ways that significantly change their shape or function, this would create a new drug in accordance with the FDA and would have to comply with their rules that regulate biology and how they are produced, processed and tested. If a doctor plans to collect stem cell-rich bone marrow from a patient, he does very little for him (minimal processing or “manipulation” in the FDA language), and then promptly introduces him into a new medicine and does not fall under FDA's jurisprudence or competence.
Currently, there are several clinics in the USA that treat patients with their own “minimally manipulated” stem cell rich in fat or bone marrow. Some of them focus on treating orthopedic problems such as arthritic joints, others on cosmetic procedures such as face lifting and breast reconstruction, as well as neurological conditions such as stroke, as well as other medical problems.
Critics asked questions about the safety and scientific assessment of at least some of these treatments. For example, while bone marrow stem cells have been shown to naturally mobilize and migrate to diseased, damaged, or infected tissues, then grafted, many scientists and physicians wonder about harvesting and administering huge amounts of bone marrow stem cells to patients. may constitute unforeseen security risk. Doctors do this by treating it as a complement to the natural process and discover that the potential benefits and rewards outweigh the risks. The case at the point: Chronic. One osteopathic doctor (see the Resource section), who treated patients with a stroke of his minimally managed bone marrow stem cells for more than five (5) years, did not find any problems and recorded improvements in many of those who were treated. Recently, some preliminary small-scale studies have confirmed that treating a stroke with stem-cell-rich bone marrow or “bone marrow aspirate” is not only safe, but it also provides clinical benefits in some patients.
In an article published on February 1, 2012 in the US News & World Report section of HealthDay, entitled “Stem Cell Therapy Shows a Promise for Stroke, Research Says” (patients can restore some functions after treatment, preliminary studies suggest), journalist Maureen Salamon discussed the results two separate studies conducted in India in which patients with stroke received stem cells from their own bone marrow. In one study, 120 moderately affected stroke patients (18 to 75 years old) were divided into two groups. Those in the stem cells or experimental group received intravenous infusions of bone marrow stem cells collected from their thighs, while in the other group this was not and served as a control. Approximately 73 percent of those in the experimental group achieved “aid independence” over the next six months, and only 61 percent of the control group. This was not statistically significant.
And in the second group, "... 40 patients, whose stroke occurred between three and 12 months earlier, were also divided into two groups: half receiving stem cells, which were dissected in saline and injected within a few hours. Compared to controls, stroke, stem cell patients showed statistically significant improvements in nutrition, dressing and mobility, according to the study. On functional MRI scans, stem cell recipients also demonstrated an increase in brain activity in regions that control movement planning and motor function. ”
According to an American expert, Ms. Salamon consulted, Dr. Matthew Fink, Head of Stroke and Critical Neurology at New York Presbyterian Hospital / Weil Cornell Medical Center, “Safety Therapy is the only thing that appeared in two studies to demonstrate “Dr. Fink also stated that“ cells taken from the bone marrow of study participants could be described as' bone marrow aspirates ”, because the authors do not prove that actual stem cells were extracted.”
As you can expect, in cases where doctors used patient stem cells that were cultured or moved beyond the “minimal manipulation”, the FDA went on the offensive. The Centeno-Schultz Colorado Clinic began orthopedic procedures (Regenexx-C), in which the patient’s own mesenchymal stem cells from the bone marrow were expanded in a special solution and reintroduced to treat moderate and fractured joints, tendons, ligaments, and bone pain. This was done as part of “approved IRB and controlled clinical trials using both the same day and cultured stem cells for orthopedic injections,” according to Chris Centeno, MD on the blog on the Regenexx blog on February 6, 2012.
After two years of treating patients who were part of an IRB approved and controlled study, Dr. Centeno and his staff felt that they had sufficient evidence of effectiveness to begin offering the procedure on a limited basis to their regular patients.
In 2008, the FDA sent a letter challenging the Regenexx ™ procedure, like creating a new drug. Dr. Centeno and his colleagues provided the FDA with numerous legal opinions, stating that what was done did not qualify as creating a new drug, and invited agency representatives to meet with them to discuss the issues raised. The FDA declined an invitation from Centeno, which was reviewed in its proprietary (Regenerative Sciences LLC) filing a lawsuit against the FDA for the first time in 2008 and again in 2010; legal proceedings aimed at forcing the agency to present its arguments in favor of categorizing the patient’s own cells as “drugs” and refer to their authority for this. Two years later (2010), the FDA filed a lawsuit against Regenerative Sciences LLC. According to Dr. Centeno, “As part of the agreement between the parties, we declare that we will use only the same day procedures in the US, and not in cultures, until the judge decides who is right in this dispute.”
In July 2011, Texas Governor Rick Perry revealed that he had a long-standing posterior problem associated with spinal fusion surgery and the injection of his own laboratory grown and grown adipose stem cells, his orthopedic surgeon Stanley Jones in Houston. According to the August 3, 2011 article that appeared in The Texas Tribune, a few weeks after his procedure, Governor Perry said in an interview with AP (Associated Press) that he felt that 80 percent recovered, swam and used a treadmill. ”
Since then, Governor Perry, Dr. Jones and other prominent Texans have actively insisted that the rules of health care in the state of Texas allow and regulate, rather than hinder the use of the patient's own stem cells by doctors from Texas. Since then, various projects have been developed, which are currently being discussed.
Unsurprisingly, the problems associated with Centeno's lawsuits and initiatives in Texas to properly regulate the use of the patient's own stem cells by doctors have caused heated, often controversial debates on issues such as how to maintain the breadth needed by doctors to conduct their own informal research in the office and take care of patient safety. Some of them are wondering if a decision that approves an FDA decision to treat more than the patient’s own autologous (own) stem cells as a new drug may not decide that states will ignore this, since seventeen of them have regarding the medical use of marijuana (allowed and regulated at the state level what was declared illegal at the federal level).
For patients who want to try any form of stem cell therapy, the options are to pursue either legal or legal, and what is not.
There are FDA-approved clinical trials on the legally authorized side that they can try to penetrate (provided they meet the criteria, i.e. meet the inclusion criteria), as well as procedures offered by private doctors who use the patient’s own stem cells that no more than “minimally controlled” were collected as part of the same procedure. They can also travel abroad for adult (non-embryonic) stem cells in a country that allows diseases such as Mexico, Panama, Thailand, or the Cayman Islands.
On the technically illegal side, there are various underground clinics and treatment programs (plus several well-known in Texas) that treat with autologous stem cells that have been cultivated or otherwise more than “minimally managed”. How many of these “underground clinics” exist and where they are located are difficult to determine for obvious reasons.
Ultimately, many people who write and blog about this “stem cell war” need medical progress that is not based on throwing patient safety into the wind and not being aggravated by restrictive laws and rules that should be given to knees. Such progress depends on how the doctor can conduct informal research of patients in the workplace. When it comes to autologous stem cells, some doctors believe that the FDA does not have a business declaring more than minimally managed stem cells to be a drug to be regulated and a new drug approval process. However, until the problem is resolved in the courts or in other areas, physicians who use autologous bone marrow or fatty stem cells as part of their research and development of more effective treatment approaches should undergo FDA "minimal manipulation" / prompt use line.
Information disclosure: The author serves the osteopathic physicist David Steenblock as a professional writer, but otherwise has no connection, commercial or otherwise, with any clinics, program or person indicated in this resource or in the Resource Block.
